Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease

Takahiro Hayashi, Tadashi Nagamatsu, Ayako Matsushita, Tomohiro Mizuno, Seira Nishibe, Ayaka Noguchi, Rina Kato, Takahiro Toda, Junko Tanaka, Hiroshi Takahashi, Hiroki Hayashi, Yukio Yuzawa, Shigeki Yamada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.

Original languageEnglish
Pages (from-to)740-745
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume38
Issue number5
DOIs
Publication statusPublished - 01-05-2015

Fingerprint

Hematinics
Chronic Renal Insufficiency
Anemia
Hemoglobins
Reference Values
Therapeutics
Dialysis
Kidney

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Hayashi, Takahiro ; Nagamatsu, Tadashi ; Matsushita, Ayako ; Mizuno, Tomohiro ; Nishibe, Seira ; Noguchi, Ayaka ; Kato, Rina ; Toda, Takahiro ; Tanaka, Junko ; Takahashi, Hiroshi ; Hayashi, Hiroki ; Yuzawa, Yukio ; Yamada, Shigeki. / Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease. In: Biological and Pharmaceutical Bulletin. 2015 ; Vol. 38, No. 5. pp. 740-745.
@article{7e351136a1654aa89820ebcb0946b813,
title = "Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease",
abstract = "Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.",
author = "Takahiro Hayashi and Tadashi Nagamatsu and Ayako Matsushita and Tomohiro Mizuno and Seira Nishibe and Ayaka Noguchi and Rina Kato and Takahiro Toda and Junko Tanaka and Hiroshi Takahashi and Hiroki Hayashi and Yukio Yuzawa and Shigeki Yamada",
year = "2015",
month = "5",
day = "1",
doi = "10.1248/bpb.b14-00844",
language = "English",
volume = "38",
pages = "740--745",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease. / Hayashi, Takahiro; Nagamatsu, Tadashi; Matsushita, Ayako; Mizuno, Tomohiro; Nishibe, Seira; Noguchi, Ayaka; Kato, Rina; Toda, Takahiro; Tanaka, Junko; Takahashi, Hiroshi; Hayashi, Hiroki; Yuzawa, Yukio; Yamada, Shigeki.

In: Biological and Pharmaceutical Bulletin, Vol. 38, No. 5, 01.05.2015, p. 740-745.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease

AU - Hayashi, Takahiro

AU - Nagamatsu, Tadashi

AU - Matsushita, Ayako

AU - Mizuno, Tomohiro

AU - Nishibe, Seira

AU - Noguchi, Ayaka

AU - Kato, Rina

AU - Toda, Takahiro

AU - Tanaka, Junko

AU - Takahashi, Hiroshi

AU - Hayashi, Hiroki

AU - Yuzawa, Yukio

AU - Yamada, Shigeki

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.

AB - Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.

UR - http://www.scopus.com/inward/record.url?scp=84929575281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929575281&partnerID=8YFLogxK

U2 - 10.1248/bpb.b14-00844

DO - 10.1248/bpb.b14-00844

M3 - Article

VL - 38

SP - 740

EP - 745

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 5

ER -